202 related articles for article (PubMed ID: 14720379)
1. [Detection of mutation and protein expression of PTEN gene in endometrial carcinoma].
Xu B; Yao Q; Dai SZ
Ai Zheng; 2004 Jan; 23(1):69-73. PubMed ID: 14720379
[TBL] [Abstract][Full Text] [Related]
2. [Study of the mutation and expression of PTEN gene in endometrial carcinoma and epithelial ovarian cancer].
Che Y; Yao Q; Dai S; Luo B; Wang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):608-11. PubMed ID: 12487936
[TBL] [Abstract][Full Text] [Related]
3. [PTEN coding product: a marker for tumorigenesis and progression of endometrial carcinoma].
Gao QL; Ye F; Li J; Xing H; Lu YP; Ma D
Ai Zheng; 2003 Jun; 22(6):640-4. PubMed ID: 12948417
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias.
Konopka B; Paszko Z; Janiec-Jankowska A; Goluda M
Cancer Lett; 2002 Apr; 178(1):43-51. PubMed ID: 11849740
[TBL] [Abstract][Full Text] [Related]
5. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
6. Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up.
Orbo A; Kaino T; Arnes M; Kopp M; Eklo K
Gynecol Oncol; 2004 Oct; 95(1):82-8. PubMed ID: 15385114
[TBL] [Abstract][Full Text] [Related]
7. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.
Risinger JI; Hayes K; Maxwell GL; Carney ME; Dodge RK; Barrett JC; Berchuck A
Clin Cancer Res; 1998 Dec; 4(12):3005-10. PubMed ID: 9865913
[TBL] [Abstract][Full Text] [Related]
8. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.
Salvesen HB; Stefansson I; Kretzschmar EI; Gruber P; MacDonald ND; Ryan A; Jacobs IJ; Akslen LA; Das S
Int J Oncol; 2004 Dec; 25(6):1615-23. PubMed ID: 15547698
[TBL] [Abstract][Full Text] [Related]
9. The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.
Konopka B; Janiec-Jankowska A; Paszko Z; Goluda M
J Cancer Res Clin Oncol; 2004 Feb; 130(2):114-21. PubMed ID: 14663583
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia.
Sun H; Enomoto T; Fujita M; Wada H; Yoshino K; Ozaki K; Nakamura T; Murata Y
Am J Clin Pathol; 2001 Jan; 115(1):32-8. PubMed ID: 11190805
[TBL] [Abstract][Full Text] [Related]
12. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.
Tashiro H; Blazes MS; Wu R; Cho KR; Bose S; Wang SI; Li J; Parsons R; Ellenson LH
Cancer Res; 1997 Sep; 57(18):3935-40. PubMed ID: 9307275
[TBL] [Abstract][Full Text] [Related]
13. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
[TBL] [Abstract][Full Text] [Related]
16. Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population.
Kanaya T; Kyo S; Sakaguchi J; Maida Y; Nakamura M; Takakura M; Hashimoto M; Mizumoto Y; Inoue M
Am J Clin Pathol; 2005 Jul; 124(1):89-96. PubMed ID: 15923161
[TBL] [Abstract][Full Text] [Related]
17. Expression of PTEN and PTEN pseudogene in endometrial carcinoma.
Yokoyama Y; Wan X; Shinohara A; Takahashi S; Takahashi Y; Niwa K; Tamaya T
Int J Mol Med; 2000 Jul; 6(1):47-50. PubMed ID: 10851265
[TBL] [Abstract][Full Text] [Related]
18. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.
Maxwell GL; Risinger JI; Gumbs C; Shaw H; Bentley RC; Barrett JC; Berchuck A; Futreal PA
Cancer Res; 1998 Jun; 58(12):2500-3. PubMed ID: 9635567
[TBL] [Abstract][Full Text] [Related]
19. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas.
Minaguchi T; Yoshikawa H; Oda K; Ishino T; Yasugi T; Onda T; Nakagawa S; Matsumoto K; Kawana K; Taketani Y
Clin Cancer Res; 2001 Sep; 7(9):2636-42. PubMed ID: 11555573
[TBL] [Abstract][Full Text] [Related]
20. Effects of mutation and expression of PTEN gene mRNA on tumorigenesis and progression of epithelial ovarian cancer.
Chen Y; Zheng H; Yang X; Sun L; Xin Y
Chin Med Sci J; 2004 Mar; 19(1):25-30. PubMed ID: 15104221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
